A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
NCT ID: NCT00001994
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atovaquone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presumptive diagnosis of AIDS.
* Cerebral toxoplasmosis.
* Expected survival of at least four weeks without therapy.
* Willing and able to give informed consent.
Prior Medication:
Allowed:
* Pyrimethamine-sulfonamide.
* Clindamycin-sulfonamide.
Exclusion Criteria
Patients with the following conditions or symptoms are excluded:
* Significant emotional disorder or psychosis.
* Evidence of significant malabsorption, ileus or significant emesis at entry which would inhibit drug absorption.
* Other known central nervous system lesions such as lymphoma, tuberculoma, cryptococcoma, active neurosyphilis. Unwilling or unable to take 566C80 with a meal, enteral supplements (eg:
* Ensure Plus) or pulverized form through a nasogastric tube.
* Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen.
Concurrent Medication:
Excluded:
* Drugs with potential anti-toxoplasmosis activity including sulfone, sulfonamide, trimethoprim, pyrimethamine and clindamycin during the acute therapy phase of the trial.
* First three weeks of treatment:
* Retrovir (zidovudine) or any investigational agent including antiretroviral agents (eg:
* ddI,ddC).
Patients with the following are excluded:
* Significant emotional disorder or psychosis.
* Evidence of significant malabsorption, ileus or significant emesis at entry which would inhibit drug absorption.
* Other known central nervous system lesions such as lymphoma, tuberculoma, cryptococcoma, active neurosyphilis. Unwilling or unable to take 566C80 with a meal, enteral supplements (eg:
* Ensure Plus) or pulverized form through a nasogastric tube.
* Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen.
Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaxo Wellcome
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles County - USC Med Ctr
Los Angeles, California, United States
Infectious Disease Med Group
Oakland, California, United States
San Francisco Gen Hosp
San Francisco, California, United States
UCSF - San Francisco Gen Hosp
San Francisco, California, United States
Davies Med Ctr
San Francisco, California, United States
Georgetown Univ Med Ctr
Washington D.C., District of Columbia, United States
Infectious Disease Research Consortium of Georgia
Atlanta, Georgia, United States
Johns Hopkins Hosp
Baltimore, Maryland, United States
Beth Israel Med Ctr
New York, New York, United States
Saint Vincent's Hosp and Med Ctr
New York, New York, United States
Harlem Hosp Ctr
New York, New York, United States
SUNY / Health Sciences Ctr at Stony Brook
Stony Brook, New York, United States
Duke Univ Med Ctr
Durham, North Carolina, United States
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, United States
Regional Med Ctr at Memphis
Memphis, Tennessee, United States
Gathe, Joseph, M.D.
Houston, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Infectious Disease Physicians Inc
Annandale, Virginia, United States
Southern Alberta HIV Clinic / Foothills Hosp
Calgary, Alberta, Canada
Dr Julio S G Montaner
Vancouver, British Columbia, Canada
Wellesley Hosp
Toronto, Ontario, Canada
Dr Emil Toma / Hotel Dieu de Montreal
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Masur H, et al. 566C80 is effective as salvage treatment for toxoplasma encephalitis. Int Conf AIDS. 1991 Jun 16-21;7(2):30 (abstract no WB31)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02
Identifier Type: -
Identifier Source: secondary_id
101A
Identifier Type: -
Identifier Source: org_study_id